The aim of this study, a retrospective evaluation of tumor samples from the NSCLC Phase III program, was to determine the prevalence of RET rearrangements and other potential RET biomarkers within this population and to investigate any association with outcome to vandetanib treatment. This evidence concerns the gene RET and neoplasm.